The use of the marker tumor concept in Ta, T1 bladder cancer: Is it justified?

Urologic Oncology

Volumn 7, Issue 1, 2002, Pages 31-33

  Van Der Meijden, Adrian P M ^a  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

Ablative treatment; Chemoresection; Marker tumor; Ta,T1 bladder tumor

Indexed keywords

BCG VACCINE; DOXORUBICIN; MITOMYCIN C; THIOTEPA; TUMOR MARKER;

BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; DRUG INSTILLATION; HUMAN; LONG TERM CARE; MEDICAL ETHICS; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR GROWTH; BLADDER CANCER; SAFETY; TRANSITIONAL CELL CARCINOMA;

ETHICS, MEDICAL; HUMANS; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0036139414     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(01)00156-9     Document Type: Review

References (12)

1. Phase II trials in Ta,T1 bladder cancer. The marker tumor concept
2. Current bladder tumor tests: Does their projected utility fulfill clinical necessity
3. Does the surgeon had an impact on the outcome pf patients with Ta,T1, T.C.C. of the bladder? Results of an EORTC quality control study on TURBT
4. Marker tumor response to the sequential combination of intravesical therapy with Mitomycin C. and BCG-RIVM in multiple superficial bladder tumors
5. The use of intravesical Thiotepa in the management of non-invasive carcinoma of the bladder
6. Marker tumor response to Evans and Pasteur Bacille Calmette-Guerin in multiple recurrent pTa, PT1 bladder tumors: Report from the Medical Researc Council subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)
7. Superficial bladder cancer: The response of a marker tumor to a single intravesical instillation of Epirubicin
8. BCG alone as treatment of superficial bladder cancer: Can TURBT be avoided?
9. Intravesical chemo- and immunotherapy: How do we assess their effectiveness and what are their limitations and uses
10. The ablative effect of quarter dose Bacillus Calmette Guerin on a papillary marker lesion of the bladder
11. A prospective European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of Epirubicin or water in single stage Ta,T1 papillary carcinoma of the bladder